Broomfield, Colorado (PRWEB) June 01, 2021 Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that the company
Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment
Laboratory Developed Test for Manual and Image Analysis-assisted Pathologist Interpretation
News provided by
Share this article
Share this article
WESTMINSTER, Colo. and CAMBRIDGE, Mass., April 12, 2021 /PRNewswire/ Flagship Biosciences, the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced a partnership to use a clinically validated tumor expression assay utilizing RNAscope
® and tissue image analysis. In a poster shared this week at the American Association for Cancer Research (AACR) Annual Meeting 2021, the companies presented data on the validation of a Dickkopf-1 (DKK1) RNAscope chromogenic in situ hybridization (CISH) assay and digital image analysis solution.
Flagship Biosciences Announces Strategic Executive Team Additions prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Spatial Genomics and Transcriptomics Market, 2030
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
Global Spatial Genomics and Transcriptomics Market to Reach $2,173.0 Million by 2030, progressing at a CAGR of 23.20%.
The market is driven by certain factors, which include the increasing prevalence of various types of genetic disorders, such as cancer, neurological disorder, and rare diseases, inciting the development of high-resolution multiplex assays and instruments, technological advancements in sequencing technologies, and significant research funding in the field of spatial-based technology for executing R&D exercises.
The market is favored by the development of spatial profiling-based solutions for visualization and analysis of tissue microenvironment, tumor biology, and tissue biomarker. The gradual increase in the prevalence of neurological disorders and rare diseases globally has furthered the spatial genomics and transcripto
Flagship Biosciences Announces Patent
Share Article
Patent Number 10,839,512 Issued for New Flagship Biosciences Tissue Sample Image Dot Detection Method
“We are pleased to announce this new patent for CISH and FISH dot detection,” said Trevor Johnson, Flagship’s CEO. “Our internal experiments show that our new method can identify and separate dots, especially if they are very close together, better than any previous method. WESTMINSTER, Colo. (PRWEB) February 17, 2021 Flagship Biosciences, the leader in data-centric pathology tissue analysis, today announced that the United States Patent and Trademark Office has issued Flagship a new patent, number 10,839,512 entitled “Method of dot detection within images of tissue samples.” The patent, one of several recent patents issued to Flagship, discloses a method to identify CISH (chromogenic in situ hybridization) and FISH (fluorescence in situ hybridizat